Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has agreed to sell $1.5 billion of senior unsecured notes: $500,000,000 million in aggregate principal amount of 1.750% notes due 2019, $500,000,000 million in aggregate principal amount of 3.250% notes due 2023 and $500,000,000 million in aggregate principal amount of 4.500% notes due 2044, in an underwritten public offering. Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BNP Paribas Securities Corp., Credit Suisse Securities (USA) LLC and RBS Securities Inc. are acting as joint book-running managers of the underwriters. Bristol-Myers Squibb intends to use the net proceeds from the offering for general corporate purposes, including the repayment of all or a portion of its commercial paper borrowings. The offering is expected to close on October 31, 2013, subject to customary closing conditions. When available, the final prospectus supplement and accompanying prospectus relating to the offering of the notes may be obtained by contacting one of the following joint book-running managers:
- Deutsche Bank Securities Inc., at: 800-503-4611
- J.P. Morgan Securities LLC, at: 212-834-4533
- Barclays Capital Inc., at: 888-603-5847
- BNP Paribas Securities Corp., at: 800-854-5674
- Credit Suisse Securities (USA) LLC, at: 800-221-1037
- RBS Securities Inc., at: 866-884-2071
Forward-Looking StatementsThis press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb's business, including those identified in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2012, particularly under "Item 1A. Risk Factors". Bristol- Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.